Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) released its earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01, Zacks reports.
Atossa Therapeutics Trading Down 1.6%
Atossa Therapeutics stock traded down $0.02 during mid-day trading on Friday, hitting $0.97. The company had a trading volume of 574,810 shares, compared to its average volume of 793,242. Atossa Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.71. The company's fifty day moving average is $0.73 and its 200-day moving average is $0.92. The company has a market capitalization of $125.31 million, a price-to-earnings ratio of -4.41 and a beta of 1.01.
Institutional Investors Weigh In On Atossa Therapeutics
An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE grew its stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 51.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 111,475 shares of the company's stock after purchasing an additional 37,809 shares during the period. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.74% of the company's stock.
Analyst Ratings Changes
ATOS has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Atossa Therapeutics in a report on Wednesday, March 26th. Ascendiant Capital Markets upped their price objective on Atossa Therapeutics from $7.00 to $7.25 and gave the stock a "buy" rating in a research report on Monday, April 21st.
View Our Latest Stock Analysis on Atossa Therapeutics
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Further Reading
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
